15908 Long-term efficacy and safety of brodalumab in patients with or without metabolic syndrome

Background: We assessed the long-term efficacy and safety of brodalumab, a fully human anti–interleukin-17 receptor A monoclonal antibody, in patients with moderate to severe plaque psoriasis, stratified by baseline metabolic syndrome (MetSyn) status.